DR. CLEMENT RICHARD BOLAND, MD
Osteopathic Medicine in Dallas, TX
License number
Texas L6798
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
3500 Gaston Ave Baylor University Medical Center (H-250), Dallas, TX 75246
Phone
(214) 820-2650
(214) 818-9292 (Fax)
(214) 740-1115
(214) 818-9292 (Fax)
(214) 740-1115
Professional information
Dr. Clement R Boland, Dallas TX - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
GI Cancer Research Lab
3500 Gaston Ave SUITE H250, Dallas 75246
(214) 820-2692 (Phone)
3500 Gaston Ave SUITE H250, Dallas 75246
(214) 820-2692 (Phone)
Certifications:
Gastroenterology, 1981, Internal Medicine, 1978
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
GI Cancer Research Lab
3500 Gaston Ave SUITE H250, Dallas 75246
Baylor Medical Center at Uptown
2727 East Lemmon Ave, Dallas 75204
3500 Gaston Ave SUITE H250, Dallas 75246
Baylor Medical Center at Uptown
2727 East Lemmon Ave, Dallas 75204
Education:
Medical School
Yale University
Graduated: 1973
St Francis Hosp
Usphs Hosp
U Calif San Francisco
Yale University
Graduated: 1973
St Francis Hosp
Usphs Hosp
U Calif San Francisco
Novel Dna Hypermethylation Diagnostic Biomarkers For Colorectal Cancer
US Patent:
2013028, Oct 31, 2013
Filed:
Oct 4, 2011
Appl. No.:
13/876568
Inventors:
Yuriko Mori - Baltimore MD, US
Stephen Meltzer - Lutherville MD, US
Ajay Goel - Dallas TX, US
Clement Boland - Dallas TX, US
Stephen Meltzer - Lutherville MD, US
Ajay Goel - Dallas TX, US
Clement Boland - Dallas TX, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
The present invention relates to the field of cancer. More specifically, the present invention relates to the use of biomarkers to detect colorectal cancer. In one aspect, the present invention provides methods for qualifying colorectal cancer status including, but not limited to, diagnosis, prognosis, and risk stratification, in patients. In one embodiment, a method for diagnosing colorectal cancer (CRC) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the methylation levels of one or more biomarkers in the sample collected from the patient; and (c) comparing the methylation levels of the one or more biomarkers with predefined methylation levels of the same biomarkers that correlate to a patient having CRC and predefined methylation levels of the same biomarkers that correlate to a patient not having CRC, wherein a correlation to one of the predefined methylation levels provides the diagnosis.
Clement Richard Boland, Dallas TX
Specialties:
Gastroenterologist
Address:
3500 Gaston Ave, Dallas, TX 75246
Education:
Yale University, School of Medicine - Doctor of Medicine
UCSF Medical Center - Fellowship - Gastroenterology (Internal Medicine)
US Public Health Service Hospital - Residency - Family Medicine
UCSF Medical Center - Fellowship - Gastroenterology (Internal Medicine)
US Public Health Service Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)
Clement Richard Boland, Dallas TX
Specialties:
Internal Medicine, Gastroenterology, Medical Genetics, Clinical Genetics, M.D., Plastic Surgery within the Head & Neck
Work:
Baylor University Medical Center
3500 Gaston Ave, Dallas, TX 75246 Regents of the University of Michigan
1500 E Medical Center Dr, Ann Arbor, MI 48109 UCSD Medicine Specialties
9350 Campus Point Dr, La Jolla, CA 92037
3500 Gaston Ave, Dallas, TX 75246 Regents of the University of Michigan
1500 E Medical Center Dr, Ann Arbor, MI 48109 UCSD Medicine Specialties
9350 Campus Point Dr, La Jolla, CA 92037
Education:
Yale University (1973)
Anti-Cancer And Anti-Inflammatory Effects Of Annurca Apple Extracts And Compositions Purified Therefrom
US Patent:
2009007, Mar 19, 2009
Filed:
Jul 30, 2008
Appl. No.:
12/182266
Inventors:
Luigi Ricciardiello - Dallas TX, US
Clement Richard Boland - Dallas TX, US
Marco Romano - Napoli, IT
Vincenzo Fogliano - Rome, IT
Clement Richard Boland - Dallas TX, US
Marco Romano - Napoli, IT
Vincenzo Fogliano - Rome, IT
Assignee:
BAYLOR RESEARCH INSTITUTE - Dallas TX
International Classification:
A61K 31/352, A61P 35/00, A61K 31/216
US Classification:
514456, 514533
Abstract:
The present invention includes compositions and methods for modulating cell proliferation using a pharmaceutical effective amount of an isolated and purified polyphenolic composition having one or more polyphenolic compounds extracted from one or more plant tissues, specifically from one or more tissues of the Annurca apple.
Chemopreventive, Anticancer And Anti-Inflammatory Effects Of Pinoresinol-Rich Olives
US Patent:
2009004, Feb 19, 2009
Filed:
Jul 29, 2008
Appl. No.:
12/182101
Inventors:
Luigi Ricciardiello - Dallas TX, US
Clement Richard Boland - Dallas TX, US
Marco Romano - Napoli, IT
Vincenzo Fogliano - Rome, IT
Clement Richard Boland - Dallas TX, US
Marco Romano - Napoli, IT
Vincenzo Fogliano - Rome, IT
International Classification:
A61K 31/7028, C12N 5/08, A61K 31/22, A61K 31/506, A61P 35/00, A61K 31/538, A61K 31/407, A61K 31/05
US Classification:
514 34, 435377, 514549, 514731, 514410, 514256, 5142298
Abstract:
The present invention relates to a composition and method for preventing and treating cancer and modulating cell proliferation using compositions extracted from pinoresinol-rich Caiazzana olives. The present invention provides contacting one or more cells with a pharmaceutical effective amount of a polyphenolic composition isolated from Caiazzana olives. The polyphenolic composition includes one or more polyphenolic compounds extracted from Caiazzana olives.
Jc Virus Vaccine
US Patent:
2008005, Mar 6, 2008
Filed:
Aug 31, 2007
Appl. No.:
11/848875
Inventors:
Clement Richard Boland - Dallas TX, US
Assignee:
BAYLOR RESEARCH INSTITUTE - Dallas TX
International Classification:
A61K 39/00, A61P 43/00
US Classification:
4242041
Abstract:
The present invention includes compositions and methods for the development and use of a vaccine that includes one or more JC virus antigens in a carrier adapted to trigger a JC virus-specific immune response in the human intestinal tract.